98110: A Randomized Phase II Dose Finding Study of ArginMax with or without Phosphodiesterase-5 Inhibitors for Its Effect on Erectile Function and Quality of Life in Survivors of Prostate Cancer Previously Treated with Radiotherapy (1 credit)
Current Accrual: 128 out of 140 patients
*The most recent WFU consent is from the 2012 Continuing Review.